Form 4 for VRTX Vertex Pharmaceuticals
Accepted 2025-02-14 00:00:00 ET · period of report 2025-02-12 · accession 0000875320-25-000071 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-02-14 | 2025-02-12 | VRTX | LEIDEN JEFFREY M | Executive COB, Dir | A - Grant | $0.00 | +7,209 | 32.6K | +28% | $0 | |
| 2025-02-14 | 2025-02-13 | VRTX | LEIDEN JEFFREY M | Executive COB, Dir | F - Tax | $450.83 | -2,525 | 30.1K | -8% | -$1.14M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-02-12 | A | A | 7,209 | $0.00 | 32,617 | D | — | — | (F1) Restricted stock unit award that fully vested upon grant. |
| 2 | Common | Common Stock | 2025-02-13 | F | D | 2,525 | $450.83 | 30,092 | D | — | — |